Inhibition of RAGE axis signaling: A pharmacological challenge
Author
dc.contributor.author
Rojas, Armando
Author
dc.contributor.author
Morales, Miguel
Author
dc.contributor.author
Gonzalez, Ileana
Author
dc.contributor.author
Araya, Paulina
Admission date
dc.date.accessioned
2019-10-15T12:23:51Z
Available date
dc.date.available
2019-10-15T12:23:51Z
Publication date
dc.date.issued
2019
Cita de ítem
dc.identifier.citation
Current Drug Targets, Volumen 20, Issue 3, 2019, Pages 340-346
Identifier
dc.identifier.issn
18735592
Identifier
dc.identifier.issn
13894501
Identifier
dc.identifier.other
10.2174/1389450119666180820105956
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/171632
Abstract
dc.description.abstract
The Receptor for Advanced Glycation End Products (RAGE) is an important cell surface receptor, which belongs to the IgG super family and is now considered as a pattern recognition receptor. Because of its relevance in many human clinical settings, it is now pursued as a very attractive therapeutic target. However, particular features of this receptor such as a wide repertoire of ligands with different binding domains, the existence of many RAGE variants as well as the presence of cytoplasmatic adaptors leading a diverse signaling, are important limitations in the search for successful pharmacological approaches to inhibit RAGE signaling. Therefore, the present review aimed to display the most promising approaches to inhibit RAGE signaling, and provide an up to date review of progress in this area.